An anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
| Member | Definition | Class |
|---|
| [5-fluoro-1-(4-isopropylbenzylidene)-2-methylinden-3-yl]acetic acid | A sulindac-based non-steroidal anti-inflammatory drug. | [5-fluoro-1-(4-isopropylbenzylidene)-2-methylinden-3-yl]acetic acid |
| 2-methoxybenzoic acid | A methoxybenzoic acid that is the methyl ether of salicylic acid. | O-methylsalicylic acid |
| 4-(5-(4-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl)benzenesulfonamide | A member of the class of pyrazoles that is 1H-pyrazole which is substituted at positions 1, 3 and 5 by 4-sulfamoylphenyl, trifluoromethyl and 4-fluorophenyl groups, respectively. A selective cyclooxygenase 2 inhibitor, it is used in veterinary medicine to treat pain and inflammation in dogs with degenerative joint disease. | mavacoxib |
| 4-biphenylylacetic acid | A monocarboxylic acid in which one of the alpha-hydrogens is substituted by a biphenyl-4-yl group. An active metabolite of fenbufen, it is used as a topical medicine to treat muscle inflammation and arthritis. | biphenyl-4-ylacetic acid |
| aceclofenac | A monocarboxylic acid that is the carboxymethyl ester of diclofenac. A non-steroidal anti-inflammatory drug related to diclofenac, it is used in the management of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. | aceclofenac |
| acemetacin | A carboxylic ester that is the carboxymethyl ester of indometacin. A non-steroidal anti-inflammatory drug, it is used in the treatment of rheumatoid arthritis, osteoarthritis, and low back pain, as well as for postoperative pain and inflammation. Its activity is due to both acemetacin and its major metabolite, indometacin. | acemetacin |
| acetaminophen | A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group. | paracetamol |
| acetosyringone | A member of the class of acetophenones that is 1-phenylethanone substituted by a hydroxy group at position 4 and methoxy groups at positions 3 and 5. | acetosyringone |
| acetovanillone | An aromatic ketone that is 1-phenylethanone substituted by a hydroxy group at position 4 and a methoxy group at position 3. | apocynin |
| adapalene | A naphthoic acid that is CD437 in which the phenolic hydroxy group has been converted to its methyl ether. | adapalene |
| alclofenac | An aromatic ether in which the ether oxygen links an allyl group to the 4-position of (3-chlorophenyl)acetic acid.A non-steroidal anti-inflammatory drug, it was withdrawn from the UK market in 1979 due to concerns with its association with vasculitis and rash. | alclofenac |
| alminoprofen | A substituted aniline that is ibuprofen in which the isobutyl group is replaced by a (2-methylprop-2-en-1-yl)amino group. A non-steroidal anti-inflammatory drug, it is used for treatment of inflammatory and rheumatic disorders. | alminoprofen |
| almotriptan | An indole compound having a 2-(dimethylamino)ethyl group at the 3-position and a (pyrrolidin-1-ylsulfonyl)methyl group at the 5-position. | almotriptan |
| amfenac | An oxo monocarboxylic acid that is benzophenone in which one of the phenyl groups is substituted by an amino group and a carboxymethyl group at position 2 and 3, respectively. The corresponding carboxamide, nepafenac, is a prodrug of amfenac and is used for the treatment of pain and inflammation following cataract surgery. | amfenac |
| aminopyrine | A pyrazolone that is 1,2-dihydro-3H-pyrazol-3-one substituted by a dimethylamino group at position 4, methyl groups at positions 1 and 5 and a phenyl group at position 2. It exhibits analgesic, anti-inflammatory, and antipyretic properties. | aminophenazone |
| amlexanox | A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position. | amlexanox |
| amodiaquine | A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position. | amodiaquine |
| ampiroxicam | A benzothiazine that is the 1-[(ethoxycarbonyl)oxy]ethyl ether of piroxicam. A prodrug for piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis. | ampiroxicam |
| ampyrone | A pyrazolone, a member of the class of pyrazoles that is antipyrine substituted at C-4 by an amino group. It is a metabolite of aminopyrine and of metamizole. | 4-aminoantipyrine |
| an2728 | A member of the class of benzoxaboroles that is 5-hydroxy-1,3-dihydro-2,1-benzoxaborole in which the phenolic hydrogen has been replaced by a 4-cyanophenyl group. A phosphodiesterase 4 inhibitor that is used for treatment of mild to moderate atopic dermatitis in children and adults. | crisaborole |
| antipyrine | A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2. | antipyrine |
| apazone | A member of the class of benzotriazines that is 1,2-dihydro-1,2,4-benzotriazine bearing a dimethylamino substitutent at position 3 and a methyl substituent at position 7 and in which the nitrogens at positions 1 and 2 are both acylated by a carboxy group of propylmalonic acid. | apazone |
| apigetrin | A glycosyloxyflavone that is apigenin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage. | apigenin 7-O-beta-D-glucoside |
| apremilast | A member of the class of isoindoles that is isoindole-1,3-dione substituted at position 4 by an acetamido group and at position 1 by a 1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl group. Used for treatment of psoriatic arthritis. | apremilast |
| aspirin | A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity. | acetylsalicylic acid |
| baicalin | The glycosyloxyflavone which is the 7-O-glucuronide of baicalein. It is an active ingredient of Chinese herbal medicine Scutellaria baicalensis. | baicalin |
| bay 11-7082 | A nitrile that is acrylonitrile in which the hydrogen located beta,trans to the cyano group is replaced by a tosyl group. It is an inhibitor of cytokine-induced IkappaB-alpha phosphorylation in cells. | (E)-3-tosylacrylonitrile |
| bendazac | A monocarboxylic acid that is glycolic acid in which the hydrogen attached to the 2-hydroxy group is replaced by a 1-benzyl-1H-indazol-3-yl group. Although it has anti-inflammatory, antinecrotic, choleretic and antilipidaemic properties and has been used for the treatment of various inflammatory skin disorders, its principal effect is to inhibit the denaturation of proteins. Its lysine salt is used in the management of cataracts. | bendazac |
| benoxaprofen | A monocarboxylic acid that is propionic acid substituted at position 2 by a 2-(4-chlorophenyl)-1,3-benzoxazol-5-yl group. It was used as a non-steroidal anti-inflammatory drug until 1982 when it was withdrawn from the market due to adverse side-effects including liver necrosis, photosensitivity, and carcinogenicity in animals. | benoxaprofen |
| benzydamine | A member of the class of indazoles carrying benzyl and 3-(dimethylamino)propyl groups at positions 1 and 3 respectively. A locally-acting nonsteroidal anti-inflammatory drug that also exhibits local anaesthetic and analgesic properties. | benzydamine |
| bromfenac | Amfenac in which the the hydrogen at the 4 position of the benzoyl group is substituted by bromine. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. It was withdrawn from the US market in 1998, following concerns over off-label abuse and hepatic failure. | bromfenac |
| bufexamac | A hydroxamic acid derived from phenylacetamide in which the benzene moiety is substituted at C-4 by a butoxy group. It has anti-inflammatory, analgesic, and antipyretic properties. | bufexamac |
| bumadizone | A carbohydrazide obtained by formal condensation of one of the carboxy groups from butylmalonic acid with the hydrazino group of 1,2-diphenylhydrazine. Used (as its calcium semihydrate) for treatment of rheumatoid arthritis. | bumadizone |
| carprofen | Propanoic acid in which one of the methylene hydrogens is substituted by a 6-chloro-9H-carbazol-2-yl group. A non-steroidal anti-inflammatory drug, it is no longer used in human medicine but is still used for treatment of arthritis in elderly dogs. | carprofen |
| caryophyllene | A beta-caryophyllene in which the stereocentre adjacent to the exocyclic double bond has S configuration while the remaining stereocentre has R configuration. It is the most commonly occurring form of beta-caryophyllene, occurring in many essential oils, particularly oil of cloves. | (-)-beta-caryophyllene |
| celecoxib | A member of the class of pyrazoles that is 1H-pyrazole which is substituted at positions 1, 3 and 5 by 4-sulfamoylphenyl, trifluoromethyl and p-tolyl groups, respectively. A cyclooxygenase-2 inhibitor, it is used in the treatment of arthritis. | celecoxib |
| cimicoxib | An imidazole substituted at positions 1, 4 and 5 by 4-aminosulfonylphenyl, chloro and 3-fluoro-4-methyoxyphenyl groups respectively. A selective cyclooxygenase 2 inhibitor, it is used in veterinary medicine for the control of pain and inflammation associated with osteoarthritis in dogs. | cimicoxib |
| clofazimine | 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients. | clofazimine |
| clonixin | A pyridinemonocarboxylic acid that is nicotinic acid substituted at position 2 by a (2-methyl-3-chlorophenyl)amino group. Used (as its lysine salt) for treatment of renal colic, muscular pain and moderately severe migraine attacks. | clonixin |
| corilagin | An ellagitannin with a hexahydroxydiphenoyl group bridging over the 3-O and 6-O of the glucose core. | corilagin |
| cox 189 | An amino acid that is phenylacetic acid which is substituted at position 2 by the nitrogen of 2-chloro-6-fluoroaniline and at position 5 by a methyl group. A highly selective cyclooxygenase 2 inhibitor, it was briefly used for the treatment of osteoarthritis, but was withdrawn due to concersns of hepatotoxicity. | lumiracoxib |
| deracoxib | A member of the class of pyrazoles that is 1H-pyrazole which is substituted at positions 1, 3, and 5 by 4-sulfamoylphenyl, difluoromethyl and 3-fluoro-4-methoxyphenyl groups, respectively. A selective cyclooxygenase 2 inhibitor, it is used in veterinary medicine for the control of pain and inflammation associated with osteoarthritis in dogs. | deracoxib |
| dexibuprofen | | dexibuprofen |
| dexketoprofen | A monocarboxylic acid that is (S)-hydratropic acid substituted at position 3 on the phenyl ring by a benzoyl group. A cyclooxygenase inhibitor, it is used to relieve short-term pain, such as muscular pain, dental pain and dysmenorrhoea. | dexketoprofen |
| diclofenac | A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position. | diclofenac |
| difenpiramide | A monocarboxylic acid amide obtained by formal condensation of the carboxy group from biphenyl-4-ylacetic acid with the amino group of 2-aminopyridine. Used for treatment of rheumatoid arthritis. | difenpiramide |
| diflunisal | An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position. | diflunisal |
| droxicam | An organic heterotricyclic compound that is 2H,5H-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide substituted at positions 3 and 5 by pyridin-2-yl and methyl groups respectively. A prodrug of piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis. | droxicam |
| eletriptan | An N-alkylpyrrolidine, that is N-methylpyrrolidine in which the pro-R hydrogen at position 2 is replaced by a {5-[2-(phenylsulfonyl)ethyl]-1H-indol-3-yl}methyl group. | eletriptan |
| enprofylline | Xanthine bearing a propyl substituent at position 3. A bronchodilator, it is used for the symptomatic treatment of asthma and chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy. | enprofylline |
| etodolac | A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active. | etodolac |
| fenbufen | | fenbufen |
| fendosal | A benzoindole that is 4,5-dihydro-3H-benzo[e]indole in which the nitrogen is substituted by a 3-carboxy-4-hydroxyphenyl group. A non-narcotic analgesic and non-steroidal anti-inflammatory drug, it has greater analgesic and inflammatory responses than aspirin but with less gastrointestinal toxicity. | fendosal |
| fenoprofen | A monocarboxylic acid that is propanoic acid in which one of the hydrogens at position 2 is substituted by a 3-phenoxyphenyl group. A non-steroidal anti-inflammatory drug, the dihydrate form of the calcium salt is used for the management of mild to moderate pain and for the relief of pain and inflammation associated with disorders such as arthritis. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding. | fenoprofen |
| fenoprofen calcium | The dihydrate form of the calcium salt of fenoprofen. A non-steroidal anti-inflammatory drug, it is used for the management of mild to moderate pain and for the relief of pain and inflammation associated with disorders such as arthritis. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding. | fenoprofen calcium |
| firocoxib | An enol ether that is the cyclopropylmethyl ether of 3-hydroxy-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]furan-2-one. A selective cyclooxygenase 2 inhibitor, it is used in veterinary medicine for the control of pain and inflammation associated with osteoarthritis in horses and dogs. | firocoxib |
| flufenamic acid | An aromatic amino acid consisting of anthranilic acid carrying an N-(trifluoromethyl)phenyl substituent. An analgesic and anti-inflammatory, it is used in rheumatic disorders. | flufenamic acid |
| flunixin | A pyridinemonocarboxylic acid that is nicotinic acid substituted at position 2 by a 2-methyl-3-(trifluoromethyl)phenylamino group. A relatively potent non-narcotic, nonsteroidal analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic properties; used in veterinary medicine (usually as the meglumine salt) for treatment of horses, cattle and pigs. | flunixin |
| flunixin meglumine | An organoammonium salt obtained by combining flunixin with one molar equivalent of 1-deoxy-1-(methylamino)-D-glucitol. A relatively potent non-narcotic, nonsteroidal analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic properties; used in veterinary medicine for treatment of horses, cattle and pigs. | flunixin meglumine |
| flunoxaprofen | A monocarboxylic acid that is propionic acid substituted at position 2 by a 2-(4-chlorophenyl)-1,3-benzoxazol-5-yl group (the S-enantiomer). Although it was shown to be effective in treatment of rheumatoid arthritis and osteoarthritis, the clinical use of flunoxaprofen was discontinued due to possible hepatotoxic side-effects. | flunoxaprofen |
| flurbiprofen | A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain. | flurbiprofen |
| garenoxacin | A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid that is substituted by a cyclopropyl group at position 1, an oxo group at position 4, a (1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl group at position 7, and a difluoromethoxy group at position 8. | garenoxacin |
| glafenine | A carboxylic ester that is 2,3-dihydroxypropyl anthranilate in which the amino group is substituted by a 7-chloroquinolin-4-yl group. A non-steroidal anti-inflammatory drug, glafenine and its hydrochloride salt were used for the relief of all types of pain, but high incidence of anaphylactic reactions resulted in their withdrawal from the market. | glafenine |
| ibufenac | A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 4-isobutylphenyl group. Although it was shown to be effective in treatment of rheumatoid arthritis, the clinical use of ibufenac was discontinued due to hepatotoxic side-effects. | ibufenac |
| ibuprofen | A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(2-methylpropyl)phenyl group. | ibuprofen |
| ibuproxam | A hydroxamic acid obtained by formal condensation of the carboxy group of ibuprofen with the amino group of hydroxylamine. Used for treatment of pain and inflammation associated with musculoskeletal and joint disorders. | ibuproxam |
| indomethacin | A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis. | indometacin |
| indoprofen | A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(1-oxo-1,3-dihydroisoindol-2-yl)phenyl group. Initially used as an anti-inflammatory and analgesic, it was withdrawn from the market due to causing severe gastrointestinal bleeding. It has been subsequently found to increase production of the survival motor neuron protein. | indoprofen |
| isoxicam | A monocarboxylic acid amide that is piroxicam in which the pyrid-2-yl group is replaced by a 5-methyl-1,2-oxazol-3-yl group. A non-steroidal anti-inflammatory drug, it was withdrawn from the market in the 1980s following its association with cases of Stevens-Johnson syndrome. | isoxicam |
| kebuzone | A pyrazolidine that is phenylbutazone in which the two methylene hydrogens at postion 3 on the butyl chain are replaced by an oxo group. | kebuzone |
| ketoprofen | An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2. | ketoprofen |
| ketorolac | A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure. | 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; ketorolac |
| leflunomide | A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide. | leflunomide |
| lonazolac | A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 3-(4-chlorophenyl)-1-phenylpyrazol-4-yl group. | lonazolac |
| lornoxicam | A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 6-chloro-4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain, primarily resulting from inflammatory diseases of the joints, osteoarthritis, surgery, sciatica and other inflammations. | lornoxicam |
| loxoprofen | A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-[(2-oxocyclopentyl)methyl]phenyl group. A prodrug that is rapidly converted into its active trans-alcohol metabolite following oral administration. | loxoprofen |
| lysine clonixinate | An organoammonium salt obtained by combining clonixin with one molar equivalent of L-lysine. Used for treatment of renal colic, muscular pain and moderately severe migraine attacks. | clonixin lysine salt |
| meclofenamate sodium anhydrous | A hydrate that is the monohydrate of the sodium salt of meclofenamic acid. It is used for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis. | sodium meclofenamate monohydrate |
| meclofenamic acid | An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,6-dichloro-3-methylphenyl group. A non-steroidal anti-inflammatory drug, it is used as the sodium salt for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis. | meclofenamic acid |
| mefenamic acid | An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis. | mefenamic acid |
| mesalamine | A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position. | mesalamine |
| metiazinic acid | Phenothiazine substituted at nitrogen by a methyl group and at C-2 by a carboxymethyl group. | metiazinic acid |
| miroprofen | A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(imidazo[1,2-a]pyridin-2-yl)phenyl group. A non-steroidal anti-inflammatory drug that also exhibits analgesic, antipyretic and platelet aggregation inhibition properties. | miroprofen |
| mk 0663 | A member of the class of bipyridines that is 2,3'-bipyridine which is substituted at the 3, 5, and 6' positions by 4-(methylsulfonyl)phenyl, chlorine, and methyl groups, respectively. | etoricoxib |
| mobic | A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis. | meloxicam |
| mobiflex | A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis. It is also indicated for short term treatment of acute musculoskeletal disorders including strains, sprains and other soft-tissue injuries. | tenoxicam |
| mofebutazone | A pyrazolidine that is phenylbutazone lacking one of the phenyl substituents. It is used for treatment of joint and muscular pain. | mofebutazone |
| nabumetone | A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs. | nabumetone |
| naproxen | A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes. | naproxen |
| naproxen sodium | An organic sodium salt consisting of equimolar amounts of naproxen(1-) anions and sodium anions. | naproxen sodium |
| naproxen-n-butyl nitrate | A carboxylic ester obtained by formal condensation of the carboxy group of naproxen with the hydroxy group of 4-(nitrooxy)butanol. A cyclooxygenase-inhibiting nitric oxide donator that is metabolised to naproxen and a nitric oxide donating moiety, effective in treatment of osteoarthritis. | naproxcinod |
| naproxol | An aromatic ether in which the substituents on oxygen are 6-[(2S)-1-hydroxypropan-2-yl]-2-naphthyl and methyl. | naproxol |
| nedocromil | | nedocromil |
| nepafenac | A monocarboxylic acid amide that is amfenac in which the carboxylic acid group has been converted into the corresponding carboxamide. It is a prodrug for amfenac, used in eye drops to treat pain and inflammation following cataract surgery. | nepafenac |
| nimesulide | An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups. | nimesulide |
| nitroflurbiprofen | A carboxylic ester obtained by formal condensation of the carboxy group of flurbiprofen with the free hydroxy group of 4-(nitrooxy)butanol. It is a non-steroidal anti-inflammatory agent showing inhibitory effects against the cyclooxygenases COX1 and COX2. | nitroflurbiprofen |
| noramidopyrine | A member of the class of pyrazoles that is antipyrine substituted at C-4 by a methylamino group. It is a metabolite of aminopyrine and of metamizole. | 4-(methylamino)antipyrine |
| olsalazine | An azobenzene that consists of two molecules of 4-aminosalicylic acid joined by an azo linkage. A prodrug for mesalazine, an anti-inflammatory drug, it is used (as the disodium salt) in the treatment of inflammatory bowel disease. | olsalazine |
| oxamethacin | A hydroxamic acid obtained by formal condensation of the carboxy group of indometacin with the amino group of hydroxylamine. | oxametacin |
| oxaprozin | A monocarboxylic acid that is a propionic acid derivative having a 4,5-diphenyl-1,3-oxazol-2-yl substituent at position 3. It is non-steroidal anti-inflammatory drug commonly used to relieve the pain and inflammatory responses associated with osteoarthritis and rheumatoid arthritis. | oxaprozin |
| oxyphenbutazone | A metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following association with blood dyscrasis and Stevens-Johnson syndrome. | oxyphenbutazone |
| parecoxib | An N-acylsulfonamide resulting from the formal condensation of valdecoxib with propionic acid. It is a prodrug for valdecoxib. | parecoxib |
| parthenolide | A sesquiterpene lactone and active principle of Feverfew (Tanacetum parthenium). | parthenolide |
| phenylbutazone | A member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position. | phenylbutazone |
| pirfenidone | A pyridone that is 2-pyridone substituted at positions 1 and 5 by phenyl and methyl groups respectively. An anti-inflammatory drug used for the treatment of idiopathic pulmonary fibrosis. | pirfenidone |
| piroxicam | A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylic acid 1,1-dioxide with the exocyclic nitrogen of 2-aminopyridine. A non-steroidal anti-inflammatory drug of the oxicam class, it is used to relieve pain and works by preventing the production of endogenous prostaglandins involved in the mediation of pain, stiffness, tenderness and swelling. | piroxicam |
| proglumetacin | A carboxylic ester obtained by formal condensation of the carboxy group of indometacin with the hydroxy group of 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl N(2)-benzoyl-N,N-dipropyl-alpha-glutaminate. Used (as its dimaleate salt) to control pain and inflammation associated with musculoskeletal and joint disorders. Following oral administration, it is metabolised to indometacin and proglumide, a drug with antisecretory effects that helps prevent injury to the stomach lining. | proglumetacin |
| propyphenazone | A pyrazolone derivative that is antipyrine substituted at C-4 by an isopropyl group. | propyphenazone |
| robenacoxib | An aromatic amino acid that is 2-amino-5-ethylphenylacetic acid in which one of the amino hydrogens is replaced by a 2,3,5,6-tetrafluorophenyl group. A selective cyclooxygenase 2 inhibitor that is used in veterinary medicine for the relief of pain and inflammation in cats and dogs. | robenacoxib |
| rofecoxib | A butenolide that is furan-2(5H)-one substituted by a phenyl group at position 3 and by a p-(methylsulfonyl)phenyl group at position 4. A selective cyclooxygenase 2 inhibitor, it was used from 1999 to 2004 for the treatment of ostoarthritis, but was withdrawn following concerns about an associated increased risk of heart attack and stroke. | rofecoxib |
| rosmarinic acid | The 1-carboxy-2-(2,4-dihydroxyphenyl)ethyl ester of trans-caffeic acid. | rosmarinic acid |
| salicin | An aryl beta-D-glucoside that is salicyl alcohol in which the phenolic hydrogen has been replaced by a beta-D-glucosyl residue. | salicin |
| salicylsalicylic acid | A dimeric benzoate ester obtained by intermolecular condensation between the carboxy of one molecule of salicylic acid with the phenol group of a second. It is a prodrug for salycylic acid that is used for treatment of rheumatoid arthritis and osteoarthritis and also shows activity against type II diabetes. | salsalate |
| sc 560 | A member of the class of pyrazoles that is 1H-pyrazole which is substituted at positions 1, 3 and 5 by 4-methoxyphenyl, trifluoromethyl and 4-chlorophenyl groups, respectively. Unlike many members of the diaryl heterocycle class of cyclooxygenase (COX) inhibitors, SC-560 is selective for COX-1. | SC560 |
| sodium bromfenac | The sesquihydrate of the sodium salt of bromfenac. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. | bromfenac sodium salt sesquihydrate |
| sulindac | A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions. | sulindac |
| sulindac sulfide | An aryl sulfide that is a metabolite of sulindac. A non-steroidal anti-inflammatory drug, which also has anticancer activity. | sulindac sulfide |
| suprofen | An aromatic ketone that is thiophene substituted at C-2 by a 4-(1-carboxyethyl)benzoyl group. | suprofen |
| suxibuzone | A pyrazolidine that is phenylbutazone which is substituted by a 3-carboxypropanoylmethyl group at the 4-position. Suxibuzone is a prodrug for phenylbutazone and is commonly used as an anti-inflammatory drug in horses. | suxibuzone |
| tepoxalin | A hydroxamic acid obtained by formal condensation of the carboxy group of 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propanoic acid with the amino group of N-methylhydroxylamine. It is used in veterinary medicine for the control of pain and inflammation caused by musculoskeletal disorders such as hip dysplasia and arthritis in dogs. | tepoxalin |
| teriflunomide | An enamide obtained by formal condensation of the carboxy group of (2Z)-2-cyano-3-hydroxybut-2-enoic acid with the anilino group of 4-(trifluoromethyl)aniline. Used for the treatment of relapsing forms of multiple sclerosis and rheumatoid arthritis. | teriflunomide |
| tiaprofenic acid | An aromatic ketone that is thiophene substituted at C-2 by benzoyl and at C-4 by a 1-carboxyethyl group. | tiaprofenic acid |
| tofisopam | An organic sodium salt having loxoprofen(1-) as the counterion. The parent acid, loxoprofen, is a prodrug that is rapidly converted to its active trans-alcohol metabolite following oral administration. | loxoprofen sodium |
| tolfenamic acid | An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 3-chloro-2-methylphenyl group. Tolfenamic acid is used specifically for relieving the pain of migraine. It also shows anticancer activity. | tolfenamic acid |
| tolmetin | A monocarboxylic acid that is (1-methylpyrrol-2-yl)acetic acid substituted at position 5 on the pyrrole ring by a 4-methylbenzoyl group. Used in the form of its sodium salt dihydrate as a nonselective nonsteroidal anti-inflammatory drug. | tolmetin |
| tolmetin sodium | An organic sodium salt that is the dihydrate form of tolmetin sodium. Used as a nonselective nonsteroidal anti-inflammatory drug. | tolmetin sodium dihydrate |
| valdecoxib | A member of the class of isoxazoles that is isoxazole which is substituted at positions 3, 4 and 5 by phenyl, p-sulfamoylphenyl and methyl groups, respectively. A selective cyclooxygenase 2-inhibitor, it used as a nonsteroidal anti-inflammatory drug (NSAID) for the treatment of arthritis from 2001 until 2005, when it was withdrawn following concerns of an associated increased risk of heart attack and stroke. | valdecoxib |
| zileuton | A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogen at position 2 is replaced by a 1-[carbamoyl(hydroxy)amino]ethyl group. A selective 5-lipoxygenase inhibitor, it inhibits the formation of leukotrienes LTB4, LTC4, LDT4, and LTE4. It is used for the management of chronic asthma. | zileuton |
| zomepirac | | zomepirac |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 24.7930 | 1 | 20 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 19.8244 | 1 | 5 |
| 67.9K protein | Vaccinia virus | Potency | 12.4422 | 2 | 14 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 36.6093 | 3 | 10 |
| acid sphingomyelinase | Homo sapiens (human) | Potency | 7.0795 | 1 | 1 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 19.7768 | 2 | 19 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 23.2587 | 2 | 23 |
| alpha-galactosidase | Homo sapiens (human) | Potency | 26.7574 | 2 | 3 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 17.1087 | 1 | 4 |
| Amyloid-beta precursor protein | Homo sapiens (human) | Potency | 2.3109 | 1 | 1 |
| AR protein | Homo sapiens (human) | Potency | 22.1359 | 12 | 177 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 22.6683 | 2 | 39 |
| arylsulfatase A | Homo sapiens (human) | Potency | 9.3313 | 1 | 9 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 18.4135 | 4 | 24 |
| Ataxin-2 | Homo sapiens (human) | Potency | 17.0165 | 2 | 10 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 7.3632 | 5 | 15 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 12.4418 | 2 | 14 |
| atrial natriuretic peptide receptor 1 precursor | Homo sapiens (human) | Potency | 0.1510 | 1 | 1 |
| atrial natriuretic peptide receptor 2 precursor | Homo sapiens (human) | Potency | 9.2683 | 1 | 1 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 13.0784 | 2 | 23 |
| BRCA1 | Homo sapiens (human) | Potency | 12.0627 | 1 | 2 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 64.2346 | 1 | 6 |
| C-terminal-binding protein 1 | Homo sapiens (human) | Potency | 3.3814 | 1 | 1 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 23.7622 | 1 | 9 |
| caspase-1 isoform alpha precursor | Homo sapiens (human) | Potency | 9.4494 | 1 | 2 |
| caspase-3 | Cricetulus griseus (Chinese hamster) | Potency | 36.1737 | 1 | 2 |
| caspase-3 | Homo sapiens (human) | Potency | 23.7622 | 1 | 9 |
| Caspase-7 | Cricetulus griseus (Chinese hamster) | Potency | 36.1737 | 1 | 2 |
| Caspase-7 | Homo sapiens (human) | Potency | 16.5311 | 1 | 2 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 28.0746 | 3 | 36 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 14.1651 | 2 | 8 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 24.2779 | 1 | 31 |
| Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 13.8182 | 1 | 4 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 31.0396 | 1 | 10 |
| Chain A, Breast cancer type 1 susceptibility protein | Homo sapiens (human) | Potency | 15.8489 | 1 | 1 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 32.8785 | 1 | 7 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 25.7255 | 2 | 8 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 22.9867 | 2 | 15 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 47.1515 | 1 | 7 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 7.8916 | 3 | 23 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 17.8627 | 1 | 17 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 13.1177 | 2 | 17 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 22.9867 | 2 | 15 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 72.0188 | 2 | 38 |
| ClpP | Bacillus subtilis | Potency | 31.6228 | 1 | 1 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 7.8775 | 1 | 10 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 17.6462 | 1 | 22 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 16.8794 | 1 | 37 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 18.5880 | 1 | 20 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 12.2846 | 1 | 5 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 17.6803 | 2 | 52 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 16.7735 | 2 | 34 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 26.0733 | 1 | 21 |
| D(1A) dopamine receptor | Homo sapiens (human) | Potency | 6.7546 | 2 | 2 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 10.1107 | 1 | 9 |
| DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 3.1623 | 1 | 1 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 45.5602 | 1 | 2 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 6.7902 | 2 | 2 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 51.0809 | 2 | 14 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 9.9923 | 1 | 9 |
| endonuclease IV | Escherichia coli | Potency | 14.3843 | 1 | 3 |
| Endothelin receptor type B | Rattus norvegicus (Norway rat) | Potency | 13.5704 | 1 | 3 |
| Endothelin-1 receptor | Rattus norvegicus (Norway rat) | Potency | 13.5704 | 1 | 3 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 18.9237 | 12 | 211 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 26.5286 | 3 | 37 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 28.5030 | 10 | 164 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 14.3818 | 1 | 44 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 16.3348 | 4 | 62 |
| eyes absent homolog 2 isoform a | Homo sapiens (human) | Potency | 3.3389 | 1 | 2 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 23.2791 | 4 | 22 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 24.2840 | 1 | 4 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 22.1135 | 1 | 4 |
| G | Vesicular stomatitis virus | Potency | 16.8794 | 1 | 37 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 17.6803 | 1 | 26 |
| GALC protein | Homo sapiens (human) | Potency | 0.7079 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 17.6803 | 1 | 26 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 17.6803 | 1 | 26 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 17.6803 | 1 | 26 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 17.6803 | 1 | 26 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 17.6803 | 1 | 26 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 17.6803 | 1 | 26 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 17.6803 | 1 | 26 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 17.6803 | 1 | 26 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 17.6803 | 1 | 26 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 17.6803 | 1 | 26 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 17.6803 | 1 | 26 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 17.6803 | 1 | 26 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 17.6803 | 1 | 26 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 17.6803 | 1 | 26 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 17.6803 | 1 | 26 |
| geminin | Homo sapiens (human) | Potency | 9.6123 | 3 | 49 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 18.4086 | 3 | 48 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 16.0463 | 2 | 10 |
| GLS protein | Homo sapiens (human) | Potency | 24.5760 | 2 | 27 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 9.1431 | 1 | 6 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 18.3076 | 4 | 47 |
| Glutamate receptor 1 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1 | 1 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 28.8470 | 2 | 18 |
| Glutamate receptor 3 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1 | 1 |
| Glutamate receptor 4 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1 | 1 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 16.9036 | 1 | 2 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 12.0201 | 1 | 4 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 15.2172 | 1 | 3 |
| heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) | Homo sapiens (human) | Potency | 21.1020 | 1 | 6 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 27.8647 | 2 | 14 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 17.9218 | 2 | 76 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 21.7046 | 1 | 19 |
| histone deacetylase 9 isoform 3 | Homo sapiens (human) | Potency | 22.3030 | 2 | 29 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 51.1494 | 2 | 17 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 41.4904 | 1 | 2 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 16.8794 | 1 | 37 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 5.5160 | 2 | 7 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 25.7320 | 2 | 5 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 30.1586 | 2 | 18 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 7.5340 | 2 | 42 |
| IDH1 | Homo sapiens (human) | Potency | 14.2600 | 1 | 11 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 57.1235 | 2 | 7 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 16.8794 | 1 | 74 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 11.6166 | 3 | 4 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 11.9496 | 1 | 3 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 11.9496 | 1 | 3 |
| Interferon beta | Homo sapiens (human) | Potency | 19.3161 | 3 | 67 |
| interleukin 8 | Homo sapiens (human) | Potency | 69.5421 | 1 | 3 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 4.8204 | 1 | 36 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 13.2657 | 1 | 3 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 25.0328 | 3 | 74 |
| luciferase | Photuris pensylvanica (Pennsylania firefly) | Potency | 14.1254 | 1 | 1 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 11.8967 | 3 | 11 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 24.6913 | 1 | 6 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 25.3094 | 2 | 18 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 12.4537 | 2 | 8 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 10.4731 | 2 | 6 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 35.3797 | 1 | 11 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 12.3121 | 1 | 4 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 12.3121 | 1 | 4 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 5.5659 | 1 | 5 |
| NFKB1 protein, partial | Homo sapiens (human) | Potency | 8.4509 | 2 | 6 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 10.7584 | 1 | 14 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 18.8236 | 1 | 7 |
| Nrf2 | Homo sapiens (human) | Potency | 10.9498 | 2 | 3 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 35.2298 | 3 | 55 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 18.2129 | 1 | 9 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 31.7276 | 2 | 19 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 18.1188 | 1 | 4 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 17.0014 | 2 | 25 |
| nuclear receptor subfamily 1, group I, member 2 | Rattus norvegicus (Norway rat) | Potency | 6.3172 | 1 | 5 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 22.8886 | 3 | 66 |
| P53 | Homo sapiens (human) | Potency | 33.1170 | 1 | 2 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 32.7030 | 1 | 6 |
| Parkin | Homo sapiens (human) | Potency | 16.6376 | 2 | 6 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 11.3228 | 2 | 20 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 71.4244 | 1 | 8 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 19.6325 | 5 | 65 |
| Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | Potency | 31.8326 | 1 | 2 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 21.6473 | 5 | 42 |
| phosphoglycerate kinase | Trypanosoma brucei brucei TREU927 | Potency | 10.9472 | 2 | 2 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 44.6603 | 2 | 21 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 4.4898 | 1 | 6 |
| Platelet-activating factor receptor | Homo sapiens (human) | Potency | 15.8489 | 1 | 1 |
| polyprotein | Zika virus | Potency | 22.1135 | 1 | 4 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 19.7409 | 1 | 5 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 18.5365 | 1 | 10 |
| PPM1D protein | Homo sapiens (human) | Potency | 22.5500 | 1 | 16 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 25.0739 | 3 | 42 |
| pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 52.1572 | 1 | 3 |
| progesterone receptor | Homo sapiens (human) | Potency | 33.0444 | 3 | 33 |
| pyruvate kinase | Leishmania mexicana mexicana | Potency | 12.6431 | 2 | 7 |
| pyruvate kinase PKM isoform a | Homo sapiens (human) | Potency | 29.5366 | 2 | 5 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 40.9903 | 1 | 3 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 21.1735 | 2 | 61 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 8.5732 | 1 | 10 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 13.7442 | 1 | 11 |
| relaxin receptor 1 isoform 1 | Homo sapiens (human) | Potency | 12.5893 | 1 | 1 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 23.1688 | 3 | 73 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 16.3043 | 4 | 61 |
| serine/threonine-protein kinase mTOR isoform 1 | Homo sapiens (human) | Potency | 2.5832 | 1 | 2 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 26.0426 | 1 | 4 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 18.9931 | 2 | 44 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 18.9931 | 2 | 44 |
| Smad3 | Homo sapiens (human) | Potency | 12.1178 | 1 | 8 |
| snurportin-1 | Homo sapiens (human) | Potency | 57.1235 | 2 | 7 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 21.7584 | 2 | 23 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 12.2261 | 2 | 17 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 20.2511 | 1 | 19 |
| TDP1 protein | Homo sapiens (human) | Potency | 15.7021 | 2 | 83 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 47.6046 | 1 | 6 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 24.5518 | 4 | 32 |
| Thrombopoietin | Homo sapiens (human) | Potency | 6.4776 | 2 | 4 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 26.5360 | 3 | 52 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 40.0620 | 4 | 8 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 17.9391 | 5 | 35 |
| thyrotropin-releasing hormone receptor | Homo sapiens (human) | Potency | 36.2228 | 2 | 2 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 32.1791 | 2 | 4 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 10.1107 | 1 | 9 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 4.4898 | 1 | 6 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 4.4898 | 1 | 6 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 41.4157 | 2 | 23 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 28.4792 | 2 | 24 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 18.3196 | 5 | 46 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 32.7770 | 5 | 26 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 28.6837 | 1 | 17 |
| Vpr | Human immunodeficiency virus 1 | Potency | 8.2852 | 1 | 2 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 10 kDa chaperonin | Escherichia coli | IC50 | 3.4225 | 2 | 4 |
| 10 kDa heat shock protein, mitochondrial | Homo sapiens (human) | IC50 | 7.1500 | 1 | 2 |
| 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase | Homo sapiens (human) | IC50 | 13.5000 | 1 | 1 |
| 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase | Homo sapiens (human) | Ki | 2.5600 | 1 | 1 |
| 3-phosphoinositide-dependent protein kinase 1 | Homo sapiens (human) | IC50 | 48.0000 | 2 | 2 |
| 3',5'-cyclic-AMP phosphodiesterase | Sus scrofa (pig) | IC50 | 1,000.0000 | 1 | 1 |
| 4-aminobutyrate aminotransferase, mitochondrial | Rattus norvegicus (Norway rat) | IC50 | 1.7500 | 1 | 4 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | IC50 | 0.1200 | 1 | 1 |
| 5-hydroxytryptamine receptor 7 | Homo sapiens (human) | IC50 | 200.0000 | 1 | 1 |
| 5-lipoxygenase | Bos taurus (cattle) | IC50 | 35.0000 | 1 | 1 |
| 6-phosphogluconate dehydrogenase, decarboxylating | Homo sapiens (human) | Ki | 37.3000 | 1 | 3 |
| 60 kDa chaperonin | Escherichia coli K-12 | IC50 | 250.0000 | 1 | 2 |
| 60 kDa chaperonin | Escherichia coli | IC50 | 3.4225 | 2 | 4 |
| 60 kDa heat shock protein, mitochondrial | Homo sapiens (human) | IC50 | 7.1500 | 1 | 2 |
| Acetylcholinesterase | Homo sapiens (human) | IC50 | 727.5550 | 2 | 2 |
| Acid-sensing ion channel 1 | Rattus norvegicus (Norway rat) | IC50 | 344.3353 | 5 | 12 |
| Acid-sensing ion channel 3 | Rattus norvegicus (Norway rat) | IC50 | 366.9618 | 1 | 4 |
| Acyl-CoA:cholesterol acyltransferase | Oryctolagus cuniculus (rabbit) | IC50 | 55.0000 | 1 | 1 |
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | IC50 | 1,444.5000 | 2 | 5 |
| Adenosine receptor A1 | Homo sapiens (human) | Ki | 43.0000 | 2 | 2 |
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | Ki | 97.3333 | 3 | 3 |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | IC50 | 1,802.2500 | 1 | 4 |
| Adenosine receptor A2a | Homo sapiens (human) | Ki | 67.7260 | 5 | 5 |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | Ki | 109.1667 | 4 | 6 |
| Adenosine receptor A2b | Homo sapiens (human) | Ki | 35.1271 | 7 | 7 |
| Adenosine receptor A2b | Rattus norvegicus (Norway rat) | Ki | 124.6000 | 3 | 5 |
| Adenosine receptor A3 | Homo sapiens (human) | IC50 | 15.9265 | 1 | 2 |
| Adenosine receptor A3 | Homo sapiens (human) | Ki | 67.1510 | 3 | 4 |
| Adenosine receptor A3 | Rattus norvegicus (Norway rat) | Ki | 65.0000 | 1 | 1 |
| Albumin | Bos taurus (cattle) | IC50 | 3.0000 | 1 | 1 |
| Albumin | Homo sapiens (human) | Ki | 171,641,481,818.1818 | 1 | 11 |
| Aldo-keto reductase family 1 member B1 | Bos taurus (cattle) | IC50 | 3.4310 | 2 | 3 |
| Aldo-keto reductase family 1 member B1 | Homo sapiens (human) | IC50 | 72.3843 | 3 | 7 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | IC50 | 4.1832 | 1 | 4 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | Ki | 4.1485 | 1 | 4 |
| Aldo-keto reductase family 1 member B10 | Homo sapiens (human) | IC50 | 17.2850 | 4 | 6 |
| Aldo-keto reductase family 1 member C1 | Homo sapiens (human) | IC50 | 53.5208 | 5 | 12 |
| Aldo-keto reductase family 1 member C1 | Homo sapiens (human) | Ki | 0.8100 | 1 | 1 |
| Aldo-keto reductase family 1 member C2 | Homo sapiens (human) | IC50 | 22.8050 | 11 | 18 |
| Aldo-keto reductase family 1 member C2 | Homo sapiens (human) | Ki | 0.2200 | 1 | 1 |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | IC50 | 4.6297 | 17 | 25 |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | Ki | 0.9863 | 4 | 6 |
| Aldo-keto reductase family 1 member C4 | Homo sapiens (human) | IC50 | 95.4000 | 3 | 10 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 15.9265 | 1 | 2 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 9.0020 | 1 | 2 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 15.9265 | 1 | 2 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 9.0020 | 1 | 2 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | IC50 | 1.5160 | 1 | 1 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | Ki | 0.6920 | 1 | 1 |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | IC50 | 10.8470 | 1 | 2 |
| Amyloid-beta precursor protein | Homo sapiens (human) | IC50 | 104.8000 | 3 | 3 |
| Androgen receptor | Homo sapiens (human) | IC50 | 51.6333 | 3 | 3 |
| Angiotensin-converting enzyme | Homo sapiens (human) | IC50 | 3,700.0000 | 1 | 1 |
| Arachidonate 5-lipoxygenase-activating protein | Homo sapiens (human) | IC50 | 22.2900 | 2 | 2 |
| Aromatase | Homo sapiens (human) | IC50 | 27.0000 | 1 | 1 |
| Aspartate aminotransferase, cytoplasmic | Homo sapiens (human) | IC50 | 21.7900 | 1 | 1 |
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 | 126.6071 | 1 | 28 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | IC50 | 12.5400 | 4 | 5 |
| Aurora kinase B | Homo sapiens (human) | IC50 | 12.1900 | 1 | 1 |
| Beta lactamase (plasmid) | Pseudomonas aeruginosa | IC50 | 43.5450 | 1 | 1 |
| Beta-3 adrenergic receptor | Homo sapiens (human) | IC50 | 16.1240 | 1 | 1 |
| Beta-3 adrenergic receptor | Homo sapiens (human) | Ki | 12.0930 | 1 | 1 |
| Beta-carbonic anhydrase 1 | Mycobacterium tuberculosis H37Rv | Ki | 11.6600 | 3 | 6 |
| Beta-lactamase | Escherichia coli K-12 | IC50 | 375.0000 | 2 | 2 |
| Beta-lactamase | Klebsiella pneumoniae | IC50 | 0.6700 | 1 | 1 |
| Bifunctional epoxide hydrolase 2 | Homo sapiens (human) | IC50 | 90.6759 | 5 | 7 |
| Bifunctional epoxide hydrolase 2 | Mus musculus (house mouse) | IC50 | 167.7500 | 2 | 2 |
| Bifunctional epoxide hydrolase 2 | Rattus norvegicus (Norway rat) | IC50 | 181.2500 | 2 | 2 |
| Bile salt export pump | Homo sapiens (human) | IC50 | 253.3804 | 7 | 71 |
| Bile salt export pump | Rattus norvegicus (Norway rat) | IC50 | 312.2429 | 1 | 7 |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | IC50 | 3.2000 | 1 | 1 |
| C-X-C chemokine receptor type 1 | Homo sapiens (human) | IC50 | 2.5405 | 3 | 4 |
| C-X-C chemokine receptor type 2 | Homo sapiens (human) | IC50 | 0.0750 | 1 | 2 |
| C-X-C chemokine receptor type 3 | Homo sapiens (human) | IC50 | 20.0250 | 1 | 2 |
| Calcium release-activated calcium channel protein 1 | Homo sapiens (human) | IC50 | 4.3000 | 1 | 1 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A | Homo sapiens (human) | IC50 | 2,803.0500 | 2 | 2 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B | Homo sapiens (human) | IC50 | 17,900.0000 | 1 | 1 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C | Homo sapiens (human) | IC50 | 71,000.0000 | 1 | 1 |
| Calcium/calmodulin-dependent protein kinase type II subunit alpha | Rattus norvegicus (Norway rat) | Ki | 5.1000 | 1 | 1 |
| Calpain-2 catalytic subunit | Homo sapiens (human) | IC50 | 0.0110 | 1 | 2 |
| cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A | Homo sapiens (human) | IC50 | 97,600.0000 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) | IC50 | 0.2004 | 6 | 7 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Homo sapiens (human) | IC50 | 5.1193 | 13 | 14 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Homo sapiens (human) | IC50 | 0.2004 | 6 | 7 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | IC50 | 0.2017 | 12 | 13 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 | 132.1417 | 2 | 24 |
| Canalicular multispecific organic anion transporter 1 | Rattus norvegicus (Norway rat) | Ki | 7.9500 | 1 | 1 |
| Cannabinoid receptor 2 | Homo sapiens (human) | Ki | 0.1500 | 1 | 1 |
| Carbonic anhydrase | Candida albicans SC5314 | Ki | 1.1135 | 3 | 8 |
| Carbonic anhydrase | Methanosarcina thermophila | Ki | 0.3800 | 2 | 4 |
| Carbonic anhydrase | Methanothermobacter thermautotrophicus str. Delta H | Ki | 49.7500 | 1 | 2 |
| Carbonic anhydrase | Saccharomyces cerevisiae S288C | Ki | 0.3810 | 1 | 2 |
| Carbonic anhydrase | Stylophora pistillata | Ki | 3.2000 | 1 | 2 |
| Carbonic anhydrase | Anopheles gambiae (African malaria mosquito) | Ki | 0.1685 | 1 | 2 |
| Carbonic anhydrase | Astrosclera willeyana | Ki | 0.6245 | 1 | 2 |
| Carbonic anhydrase | Cryptococcus neoformans var. grubii | Ki | 1.8800 | 1 | 2 |
| Carbonic anhydrase | Mycobacterium tuberculosis H37Rv | Ki | 7.7850 | 1 | 2 |
| Carbonic anhydrase | Nakaseomyces glabratus CBS 138 | Ki | 0.1065 | 1 | 2 |
| Carbonic anhydrase | Stylophora pistillata | Ki | 0.0314 | 2 | 4 |
| Carbonic anhydrase | Sulfurihydrogenibium sp. YO3AOP1 | Ki | 0.0061 | 1 | 2 |
| Carbonic anhydrase 1 | Homo sapiens (human) | IC50 | 339.1952 | 6 | 26 |
| Carbonic anhydrase 1 | Homo sapiens (human) | Ki | 142.6383 | 44 | 92 |
| Carbonic anhydrase 12 | Homo sapiens (human) | Ki | 76.7916 | 9 | 25 |
| Carbonic anhydrase 13 | Homo sapiens (human) | Ki | 0.2070 | 2 | 3 |
| Carbonic anhydrase 13 | Mus musculus (house mouse) | Ki | 139.0161 | 3 | 14 |
| Carbonic anhydrase 14 | Homo sapiens (human) | Ki | 120.4741 | 4 | 16 |
| Carbonic anhydrase 15 | Mus musculus (house mouse) | Ki | 1.2704 | 4 | 8 |
| Carbonic anhydrase 2 | Homo sapiens (human) | IC50 | 251.9749 | 7 | 28 |
| Carbonic anhydrase 2 | Homo sapiens (human) | Ki | 52.0308 | 54 | 109 |
| Carbonic anhydrase 2 | Mycobacterium tuberculosis H37Rv | Ki | 0.6975 | 2 | 4 |
| Carbonic anhydrase 3 | Homo sapiens (human) | Ki | 167.7778 | 5 | 18 |
| Carbonic anhydrase 4 | Bos taurus (cattle) | IC50 | 50.3134 | 3 | 19 |
| Carbonic anhydrase 4 | Bos taurus (cattle) | Ki | 0.3150 | 2 | 4 |
| Carbonic anhydrase 4 | Homo sapiens (human) | Ki | 92.0543 | 7 | 21 |
| Carbonic anhydrase 5A, mitochondrial | Homo sapiens (human) | Ki | 170.0000 | 4 | 16 |
| Carbonic anhydrase 5B, mitochondrial | Homo sapiens (human) | Ki | 138.2359 | 4 | 16 |
| Carbonic anhydrase 6 | Homo sapiens (human) | Ki | 117.0774 | 6 | 22 |
| Carbonic anhydrase 7 | Homo sapiens (human) | Ki | 84.9226 | 8 | 23 |
| Carbonic anhydrase 9 | Homo sapiens (human) | IC50 | 44.4558 | 3 | 9 |
| Carbonic anhydrase 9 | Homo sapiens (human) | Ki | 52.5270 | 18 | 40 |
| Carbonic anhydrase, alpha family | Hydrogenovibrio crunogenus XCL-2 | Ki | 0.7550 | 1 | 2 |
| Carboxylic ester hydrolase | Rattus norvegicus (Norway rat) | IC50 | 10.0000 | 1 | 1 |
| caspase recruitment domain family, member 15 | Homo sapiens (human) | IC50 | 6.6330 | 1 | 1 |
| Caspase-1 | Homo sapiens (human) | IC50 | 12.6032 | 1 | 40 |
| Caspase-3 | Homo sapiens (human) | IC50 | 12.6033 | 1 | 40 |
| Caspase-4 | Homo sapiens (human) | IC50 | 12.6032 | 1 | 40 |
| Caspase-5 | Homo sapiens (human) | IC50 | 12.6033 | 1 | 40 |
| Caspase-9 | Homo sapiens (human) | IC50 | 12.6032 | 1 | 40 |
| Catechol O-methyltransferase | Mus musculus (house mouse) | IC50 | 4.5240 | 2 | 3 |
| Cell division control protein 42 homolog | Homo sapiens (human) | IC50 | 2.0000 | 1 | 1 |
| cGMP-dependent 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | IC50 | 3,630.0000 | 1 | 1 |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | IC50 | 32,003.2000 | 2 | 2 |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | IC50 | 29,403.2000 | 2 | 2 |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | IC50 | 18,745.6667 | 3 | 3 |
| Chain A, Carbonic anhydrase II | Homo sapiens (human) | IC50 | 0.0210 | 1 | 1 |
| Chain A, Carbonic anhydrase II | Homo sapiens (human) | Ki | 0.0430 | 1 | 1 |
| Chain A, Histamine N-methyltransferase | Homo sapiens (human) | Ki | 0.0186 | 1 | 4 |
| Chain A, membrane-associated prostaglandin E synthase-2 | Macaca fascicularis (crab-eating macaque) | IC50 | 1,000.0000 | 1 | 1 |
| Cholinesterase | Homo sapiens (human) | IC50 | 600.0000 | 1 | 1 |
| Chymotrypsinogen A | Bos taurus (cattle) | IC50 | 200.0000 | 1 | 1 |
| Class A sortase SrtA | Staphylococcus aureus | IC50 | 129.0000 | 1 | 1 |
| Cruzipain | Trypanosoma cruzi | IC50 | 103.0000 | 4 | 6 |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | IC50 | 14.3600 | 1 | 1 |
| Cyclooxygenase-2 | Canis lupus familiaris (dog) | IC50 | 1.7733 | 2 | 3 |
| Cystathionine gamma-lyase | Homo sapiens (human) | IC50 | 200.0000 | 1 | 2 |
| cysteine protease ATG4B isoform a | Homo sapiens (human) | IC50 | 8.1700 | 1 | 1 |
| Cysteinyl leukotriene receptor 1 | Homo sapiens (human) | IC50 | 14.8940 | 2 | 2 |
| Cysteinyl leukotriene receptor 1 | Homo sapiens (human) | Ki | 14.6840 | 1 | 1 |
| Cysteinyl leukotriene receptor 2 | Homo sapiens (human) | IC50 | 0.4200 | 1 | 1 |
| Cystine/glutamate transporter | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| Cytochrome c oxidase subunit 1 | Homo sapiens (human) | IC50 | 15.0000 | 1 | 1 |
| Cytochrome c oxidase subunit 1 | Ovis aries (sheep) | IC50 | 38.5625 | 4 | 4 |
| Cytochrome c oxidase subunit 2 | Homo sapiens (human) | IC50 | 9.8786 | 7 | 12 |
| Cytochrome c oxidase subunit 2 | Ovis aries (sheep) | IC50 | 0.0882 | 4 | 4 |
| Cytochrome P450 1A2 | Homo sapiens (human) | IC50 | 4.3750 | 2 | 4 |
| Cytochrome P450 1A2 | Homo sapiens (human) | Ki | 117.0000 | 1 | 1 |
| Cytochrome P450 2C19 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Cytochrome P450 2C9 | Homo sapiens (human) | IC50 | 40.7850 | 3 | 14 |
| Cytochrome P450 2C9 | Homo sapiens (human) | Ki | 108,925,666,686.2833 | 4 | 6 |
| Cytochrome P450 2D6 | Homo sapiens (human) | IC50 | 7.0000 | 3 | 3 |
| Cytochrome P450 2J2 | Homo sapiens (human) | IC50 | 45.9158 | 1 | 12 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 | 204.1200 | 4 | 5 |
| Cytochrome P450 3A4 | Homo sapiens (human) | Ki | 1,640.0000 | 1 | 3 |
| Cytochrome P450 3A5 | Homo sapiens (human) | IC50 | 0.3000 | 1 | 2 |
| Cytosolic phospholipase A2 gamma | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| D(1A) dopamine receptor | Homo sapiens (human) | IC50 | 27.9080 | 1 | 2 |
| D(1A) dopamine receptor | Homo sapiens (human) | Ki | 13.9540 | 1 | 2 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 10.2150 | 2 | 2 |
| Dehydrogenase/reductase SDR family member 9 | Homo sapiens (human) | IC50 | 14.0000 | 1 | 1 |
| Dehydrogenase/reductase SDR family member 9 | Rattus norvegicus (Norway rat) | IC50 | 100.0000 | 1 | 1 |
| Delta carbonic anhydrase | Conticribra weissflogii | Ki | 0.3215 | 1 | 2 |
| Delta-type opioid receptor | Mus musculus (house mouse) | Ki | 26.0160 | 2 | 4 |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | Ki | 0.0320 | 1 | 2 |
| Dihydrofolate reductase | Homo sapiens (human) | IC50 | 0.3880 | 1 | 1 |
| Dihydrofolate reductase | Homo sapiens (human) | Ki | 1,426.5714 | 1 | 7 |
| Dihydroorotate dehydrogenase | Leishmania major | IC50 | 102.7000 | 1 | 2 |
| Dihydroorotate dehydrogenase | Plasmodium falciparum (malaria parasite P. falciparum) | IC50 | 98.8725 | 4 | 4 |
| Dihydroorotate dehydrogenase | Schistosoma mansoni | IC50 | 50.0000 | 2 | 2 |
| Dihydroorotate dehydrogenase | Plasmodium falciparum (malaria parasite P. falciparum) | Ki | 22.6750 | 2 | 2 |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Homo sapiens (human) | IC50 | 2.2956 | 24 | 25 |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Mus musculus (house mouse) | IC50 | 0.1030 | 4 | 5 |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Rattus norvegicus (Norway rat) | IC50 | 0.0160 | 6 | 7 |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Homo sapiens (human) | Ki | 0.9207 | 3 | 3 |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | IC50 | 225.0000 | 1 | 1 |
| DNA repair protein RAD52 homolog | Homo sapiens (human) | IC50 | 1.0000 | 2 | 2 |
| DNA topoisomerase 1 | Homo sapiens (human) | IC50 | 40.0000 | 1 | 1 |
| Epidermal growth factor receptor | Homo sapiens (human) | IC50 | 12.3302 | 2 | 6 |
| Estrogen receptor 1 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 3 |
| Fatty acid-binding protein, intestinal | Homo sapiens (human) | Ki | 54.4500 | 2 | 10 |
| Fatty acid-binding protein, liver | Rattus norvegicus (Norway rat) | Ki | 369.9218 | 2 | 14 |
| Fatty-acid amide hydrolase 1 | Rattus norvegicus (Norway rat) | IC50 | 71.2600 | 3 | 5 |
| fMet-Leu-Phe receptor | Homo sapiens (human) | IC50 | 5.3000 | 1 | 1 |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | IC50 | 14.3600 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | IC50 | 44.4833 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit delta | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit epsilon | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit pi | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit theta | Homo sapiens (human) | Ki | 77.6247 | 1 | 1 |
| Gamma-secretase subunit APH-1A | Homo sapiens (human) | IC50 | 147.9200 | 5 | 5 |
| Gamma-secretase subunit APH-1B | Homo sapiens (human) | IC50 | 147.9200 | 5 | 5 |
| Gamma-secretase subunit PEN-2 | Homo sapiens (human) | IC50 | 147.9200 | 5 | 5 |
| Glucose-6-phosphate 1-dehydrogenase | Homo sapiens (human) | Ki | 57.9000 | 1 | 1 |
| glucose-6-phosphate 1-dehydrogenase isoform b | Homo sapiens (human) | IC50 | 80.0000 | 1 | 1 |
| glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase | Plasmodium berghei | IC50 | 63.1250 | 3 | 4 |
| Glutathione hydrolase 1 proenzyme | Homo sapiens (human) | IC50 | 36.0000 | 1 | 1 |
| Glutathione reductase, mitochondrial | Homo sapiens (human) | Ki | 6.1000 | 1 | 1 |
| High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A | Homo sapiens (human) | IC50 | 1,015.3650 | 2 | 2 |
| Histone deacetylase 1 | Homo sapiens (human) | IC50 | 1.4110 | 2 | 2 |
| Histone deacetylase 11 | Homo sapiens (human) | IC50 | 1.6370 | 1 | 1 |
| Histone deacetylase 2 | Homo sapiens (human) | IC50 | 1.6370 | 1 | 1 |
| Histone deacetylase 3 | Homo sapiens (human) | IC50 | 1.6370 | 1 | 1 |
| Histone deacetylase 4 | Homo sapiens (human) | IC50 | 1.6370 | 1 | 1 |
| Histone deacetylase 5 | Homo sapiens (human) | IC50 | 1.6370 | 1 | 1 |
| Histone deacetylase 6 | Homo sapiens (human) | IC50 | 1.1400 | 2 | 2 |
| Histone deacetylase 7 | Homo sapiens (human) | IC50 | 1.6370 | 1 | 1 |
| Histone deacetylase 8 | Homo sapiens (human) | IC50 | 1.6370 | 1 | 1 |
| Histone deacetylase 9 | Homo sapiens (human) | IC50 | 1.6370 | 1 | 1 |
| Hormone-sensitive lipase | Rattus norvegicus (Norway rat) | IC50 | 1.2000 | 1 | 1 |
| Hydroxyacid oxidase 1 | Mus musculus (house mouse) | IC50 | 7.8000 | 1 | 1 |
| Indoleamine 2,3-dioxygenase 1 | Mus musculus (house mouse) | IC50 | 0.0440 | 1 | 4 |
| Inhibitor of nuclear factor kappa-B kinase subunit epsilon | Homo sapiens (human) | IC50 | 5.1143 | 1 | 2 |
| integrase, partial | Human immunodeficiency virus 1 | IC50 | 3.5596 | 2 | 2 |
| Integrin alpha-IIb | Homo sapiens (human) | IC50 | 52.5000 | 2 | 2 |
| Integrin beta-3 | Homo sapiens (human) | IC50 | 52.5000 | 2 | 2 |
| Interleukin-8 | Homo sapiens (human) | IC50 | 0.2870 | 1 | 4 |
| Interstitial collagenase | Homo sapiens (human) | IC50 | 23.3450 | 1 | 1 |
| Lactoylglutathione lyase | Homo sapiens (human) | Ki | 293.5947 | 3 | 19 |
| large T antigen | Betapolyomavirus macacae | IC50 | 19.1000 | 1 | 1 |
| lens epithelium-derived growth factor p75 | Homo sapiens (human) | IC50 | 3.5596 | 2 | 2 |
| leucine aminopeptidase | Homo sapiens (human) | IC50 | 0.3100 | 1 | 1 |
| Leukotriene A-4 hydrolase | Homo sapiens (human) | IC50 | 66.6743 | 3 | 3 |
| Leukotriene B4 receptor 1 | Homo sapiens (human) | IC50 | 0.4200 | 1 | 1 |
| Lysine-specific histone demethylase 1A | Homo sapiens (human) | IC50 | 3.1900 | 3 | 3 |
| M1-family alanyl aminopeptidase | Plasmodium falciparum 3D7 | IC50 | 47.5850 | 2 | 2 |
| M17 leucyl aminopeptidase | Plasmodium falciparum 3D7 | IC50 | 0.7050 | 2 | 2 |
| M18 aspartyl aminopeptidase | Plasmodium falciparum 3D7 | IC50 | 10.0200 | 1 | 1 |
| Malate dehydrogenase, cytoplasmic | Homo sapiens (human) | IC50 | 200.0000 | 1 | 2 |
| microphthalmia-associated transcription factor isoform 9 | Homo sapiens (human) | IC50 | 2.6728 | 3 | 9 |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | IC50 | 3.3877 | 1 | 3 |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | IC50 | 55.5800 | 3 | 3 |
| Mothers against decapentaplegic homolog 3 | Mus musculus (house mouse) | IC50 | 1.4300 | 1 | 1 |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | IC50 | 36.8667 | 1 | 3 |
| Mu-type opioid receptor | Homo sapiens (human) | IC50 | 33.6680 | 1 | 1 |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | Ki | 0.0320 | 1 | 2 |
| Mu-type opioid receptor | Homo sapiens (human) | Ki | 13.6670 | 1 | 1 |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | Ki | 52.0000 | 1 | 2 |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | IC50 | 500.0000 | 1 | 2 |
| Multidrug resistance-associated protein 1 | Homo sapiens (human) | IC50 | 12.3000 | 2 | 2 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 | 104.3464 | 1 | 28 |
| Myc proto-oncogene protein | Homo sapiens (human) | IC50 | 403.0000 | 1 | 1 |
| Myeloperoxidase | Homo sapiens (human) | IC50 | 51.3225 | 4 | 4 |
| Myoglobin | Homo sapiens (human) | IC50 | 2.3000 | 1 | 1 |
| NACHT, LRR and PYD domains-containing protein 3 | Mus musculus (house mouse) | IC50 | 18.5000 | 2 | 2 |
| Neuraminidase | Influenza A virus (A/Wilson-Smith/1933(H1N1)) | IC50 | 100.0000 | 1 | 1 |
| Neuraminidase | Influenza A virus (A/Wilson-Smith/1933(H1N1)) | IC50 | 46.9000 | 1 | 1 |
| Neuraminidase | Influenza A virus (A/Wilson-Smith/1933(H1N1)) | Ki | 53.8000 | 1 | 1 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | IC50 | 13.3070 | 1 | 2 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | IC50 | 13.3070 | 1 | 2 |
| Nicastrin | Homo sapiens (human) | IC50 | 147.9200 | 5 | 5 |
| Nicotinate phosphoribosyltransferase | Homo sapiens (human) | Ki | 0.0004 | 1 | 8 |
| Nitric oxide synthase, inducible | Mus musculus (house mouse) | IC50 | 24.3500 | 5 | 5 |
| Nuclear factor NF-kappa-B p100 subunit | Homo sapiens (human) | IC50 | 2.0000 | 1 | 1 |
| Nuclear factor NF-kappa-B p105 subunit | Homo sapiens (human) | IC50 | 2.0000 | 1 | 1 |
| Nuclear receptor subfamily 4 group A member 2 | Homo sapiens (human) | IC50 | 26.7000 | 1 | 2 |
| P2Y purinoceptor 12 | Rattus norvegicus (Norway rat) | IC50 | 0.3400 | 1 | 3 |
| phospholipase A2 precursor | Homo sapiens (human) | IC50 | 7.7400 | 1 | 1 |
| Phospholipase A2, major isoenzyme | Sus scrofa (pig) | IC50 | 1,000.0000 | 1 | 1 |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | IC50 | 1.6370 | 1 | 1 |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | IC50 | 4.4733 | 76 | 78 |
| Polyunsaturated fatty acid 5-lipoxygenase | Mus musculus (house mouse) | IC50 | 0.1900 | 1 | 1 |
| Polyunsaturated fatty acid 5-lipoxygenase | Rattus norvegicus (Norway rat) | IC50 | 117.9287 | 28 | 37 |
| Polyunsaturated fatty acid lipoxygenase ALOX12 | Homo sapiens (human) | IC50 | 55.0000 | 1 | 1 |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Homo sapiens (human) | IC50 | 0.4000 | 1 | 1 |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | IC50 | 28.3800 | 1 | 1 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 | 301.9950 | 1 | 1 |
| Presenilin-1 | Homo sapiens (human) | IC50 | 147.9200 | 5 | 5 |
| Presenilin-2 | Homo sapiens (human) | IC50 | 147.9200 | 5 | 5 |
| Procathepsin L | Homo sapiens (human) | IC50 | 4.7600 | 1 | 3 |
| Prolyl endopeptidase | Homo sapiens (human) | IC50 | 12.1500 | 2 | 2 |
| Prostaglandin D2 receptor | Mus musculus (house mouse) | IC50 | 10.0000 | 1 | 1 |
| Prostaglandin D2 receptor | Mus musculus (house mouse) | Ki | 10.0000 | 2 | 2 |
| Prostaglandin D2 receptor 2 | Homo sapiens (human) | Ki | 3.8500 | 3 | 3 |
| Prostaglandin E synthase | Homo sapiens (human) | IC50 | 24.4330 | 5 | 5 |
| Prostaglandin E2 receptor EP1 subtype | Mus musculus (house mouse) | Ki | 10.0000 | 2 | 2 |
| Prostaglandin E2 receptor EP2 subtype | Mus musculus (house mouse) | Ki | 10.0000 | 2 | 2 |
| Prostaglandin E2 receptor EP3 subtype | Mus musculus (house mouse) | Ki | 10.0000 | 2 | 2 |
| Prostaglandin E2 receptor EP4 subtype | Mus musculus (house mouse) | Ki | 10.0000 | 2 | 2 |
| Prostaglandin G/H synthase 1 | Canis lupus familiaris (dog) | IC50 | 14.2850 | 1 | 2 |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | IC50 | 34.1904 | 159 | 295 |
| Prostaglandin G/H synthase 1 | Mus musculus (house mouse) | IC50 | 3.2802 | 9 | 12 |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | IC50 | 195.1291 | 223 | 430 |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | Ki | 62.0000 | 1 | 1 |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | Ki | 5.9667 | 3 | 3 |
| Prostaglandin G/H synthase 1 | Bos taurus (cattle) | IC50 | 393.8664 | 17 | 37 |
| Prostaglandin G/H synthase 1 | Rattus norvegicus (Norway rat) | IC50 | 7.8685 | 16 | 25 |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | IC50 | 56.2684 | 294 | 535 |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | IC50 | 4.0164 | 41 | 59 |
| Prostaglandin G/H synthase 2 | Oryctolagus cuniculus (rabbit) | IC50 | 18.0000 | 1 | 1 |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | IC50 | 96.4749 | 98 | 176 |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | Ki | 7.7084 | 4 | 7 |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | Ki | 6.4500 | 3 | 3 |
| Prostaglandin G/H synthase 2 | Bos taurus (cattle) | IC50 | 165.9987 | 9 | 19 |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | IC50 | 5.7134 | 16 | 25 |
| Prostaglandin-H2 D-isomerase | Mus musculus (house mouse) | IC50 | 375.6000 | 2 | 4 |
| Protein kinase C alpha type | Rattus norvegicus (Norway rat) | IC50 | 20.0000 | 1 | 2 |
| Protein kinase C beta type | Rattus norvegicus (Norway rat) | IC50 | 20.0000 | 1 | 2 |
| Protein kinase C delta type | Rattus norvegicus (Norway rat) | IC50 | 20.0000 | 1 | 2 |
| Protein kinase C epsilon type | Rattus norvegicus (Norway rat) | IC50 | 20.0000 | 1 | 2 |
| Protein kinase C eta type | Rattus norvegicus (Norway rat) | IC50 | 20.0000 | 1 | 2 |
| Protein kinase C gamma type | Rattus norvegicus (Norway rat) | IC50 | 20.0000 | 1 | 2 |
| Protein kinase C theta type | Rattus norvegicus (Norway rat) | IC50 | 20.0000 | 1 | 2 |
| Protein kinase C zeta type | Rattus norvegicus (Norway rat) | IC50 | 20.0000 | 1 | 2 |
| Protein-arginine deiminase type-4 | Homo sapiens (human) | IC50 | 6,200.0000 | 1 | 2 |
| Pyruvate kinase PKM | Homo sapiens (human) | IC50 | 21.0000 | 1 | 1 |
| Quinolone resistance protein NorA | Staphylococcus aureus | IC50 | 40.0000 | 1 | 1 |
| rac GTPase-activating protein 1 isoform a | Homo sapiens (human) | IC50 | 35.0000 | 1 | 1 |
| Ras-related C3 botulinum toxin substrate 1 | Homo sapiens (human) | IC50 | 2.0000 | 1 | 1 |
| receptor-interacting serine/threonine-protein kinase 2 isoform 1 | Homo sapiens (human) | IC50 | 6.6330 | 1 | 1 |
| Replicase polyprotein 1ab | Betacoronavirus England 1 | IC50 | 10.0000 | 1 | 2 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | IC50 | 5.4317 | 6 | 7 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | IC50 | 6.4100 | 1 | 1 |
| Retinoic acid receptor alpha | Homo sapiens (human) | Ki | 1.1000 | 1 | 1 |
| Retinoic acid receptor beta | Homo sapiens (human) | Ki | 0.0340 | 1 | 1 |
| Retinoic acid receptor gamma | Homo sapiens (human) | Ki | 0.1300 | 1 | 1 |
| Retinoic acid receptor RXR-alpha | Homo sapiens (human) | IC50 | 42.6500 | 1 | 2 |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | IC50 | 6,700.0000 | 1 | 1 |
| Rho-associated protein kinase 2 | Rattus norvegicus (Norway rat) | IC50 | 53.8500 | 1 | 4 |
| RNA-directed RNA polymerase | | IC50 | 20.0000 | 1 | 1 |
| Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | IC50 | 38.0600 | 2 | 7 |
| Serine hydroxymethyltransferase, mitochondrial | Homo sapiens (human) | IC50 | 1.9498 | 1 | 1 |
| Serine/threonine-protein kinase PAK 1 | Homo sapiens (human) | IC50 | 36.0000 | 1 | 1 |
| Serine/threonine-protein kinase PLK1 | Homo sapiens (human) | IC50 | 3.6100 | 1 | 1 |
| Serine/threonine-protein kinase TBK1 | Homo sapiens (human) | IC50 | 0.8506 | 1 | 2 |
| Serum paraoxonase/arylesterase 1 | Homo sapiens (human) | Ki | 3,355.5000 | 1 | 4 |
| Sialidase | Clostridium perfringens | IC50 | 39.3000 | 1 | 1 |
| Sigma intracellular receptor 2 | Rattus norvegicus (Norway rat) | IC50 | 0.2700 | 1 | 2 |
| Sodium- and chloride-dependent betaine transporter | Rattus norvegicus (Norway rat) | IC50 | 0.3500 | 1 | 2 |
| Sodium- and chloride-dependent GABA transporter 1 | Rattus norvegicus (Norway rat) | IC50 | 0.3500 | 1 | 2 |
| Sodium- and chloride-dependent GABA transporter 2 | Rattus norvegicus (Norway rat) | IC50 | 0.3500 | 1 | 2 |
| Sodium- and chloride-dependent GABA transporter 3 | Rattus norvegicus (Norway rat) | IC50 | 0.3500 | 1 | 2 |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | IC50 | 14.0000 | 1 | 1 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | IC50 | 6.7330 | 1 | 3 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | Ki | 5.3493 | 1 | 3 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | IC50 | 4.1832 | 1 | 4 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | Ki | 4.1485 | 1 | 4 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | IC50 | 6.2760 | 1 | 1 |
| Sodium-dependent serotonin transporter | Macaca mulatta (Rhesus monkey) | IC50 | 0.5000 | 1 | 1 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | Ki | 3.3340 | 1 | 1 |
| Sodium/hydrogen exchanger 1 | Rattus norvegicus (Norway rat) | IC50 | 18.5000 | 1 | 2 |
| Solute carrier family 22 member 11 | Homo sapiens (human) | Ki | 107.8000 | 1 | 1 |
| Solute carrier family 22 member 20 | Mus musculus (house mouse) | Ki | 51.3878 | 1 | 4 |
| Solute carrier family 22 member 6 | Homo sapiens (human) | IC50 | 9.6350 | 2 | 10 |
| Solute carrier family 22 member 6 | Rattus norvegicus (Norway rat) | IC50 | 0.5000 | 1 | 1 |
| Solute carrier family 22 member 6 | Homo sapiens (human) | Ki | 19.8000 | 1 | 1 |
| Solute carrier family 22 member 6 | Mus musculus (house mouse) | Ki | 347.0521 | 1 | 4 |
| Solute carrier family 22 member 6 | Rattus norvegicus (Norway rat) | Ki | 303.4111 | 3 | 9 |
| Solute carrier family 22 member 7 | Rattus norvegicus (Norway rat) | Ki | 1.8400 | 1 | 1 |
| Solute carrier family 22 member 8 | Homo sapiens (human) | Ki | 595.9217 | 2 | 6 |
| Solute carrier organic anion transporter family member 1A1 | Rattus norvegicus (Norway rat) | Ki | 126.0000 | 1 | 1 |
| Solute carrier organic anion transporter family member 1A3 | Rattus norvegicus (Norway rat) | Ki | 1,450.0000 | 1 | 2 |
| Solute carrier organic anion transporter family member 1A4 | Rattus norvegicus (Norway rat) | Ki | 2,430.0000 | 1 | 1 |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | IC50 | 12.0000 | 1 | 1 |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | Ki | 11.0000 | 1 | 1 |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | IC50 | 41.0000 | 1 | 1 |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | Ki | 38.0000 | 1 | 1 |
| Solute carrier organic anion transporter family member 2B1 | Homo sapiens (human) | IC50 | 140.0000 | 1 | 1 |
| Solute carrier organic anion transporter family member 2B1 | Homo sapiens (human) | Ki | 130.0000 | 1 | 1 |
| Squalene monooxygenase | Rattus norvegicus (Norway rat) | IC50 | 4.0000 | 1 | 1 |
| Stromal interaction molecule 1 | Homo sapiens (human) | IC50 | 4.3000 | 1 | 1 |
| Substance-P receptor | Cavia porcellus (domestic guinea pig) | IC50 | 3.0667 | 1 | 3 |
| Thiosulfate sulfurtransferase | Homo sapiens (human) | IC50 | 50.1400 | 1 | 2 |
| Thromboxane-A synthase | Rattus norvegicus (Norway rat) | IC50 | 20.0000 | 1 | 1 |
| Thromboxane-A synthase | Homo sapiens (human) | IC50 | 50.0500 | 2 | 2 |
| Toll-like receptor 4 | Homo sapiens (human) | IC50 | 1.4000 | 1 | 1 |
| Transcription factor p65 | Homo sapiens (human) | IC50 | 2.5000 | 2 | 2 |
| Transcription factor SOX-18 | Mus musculus (house mouse) | IC50 | 191.5000 | 2 | 4 |
| Transcriptional enhancer factor TEF-3 | Homo sapiens (human) | IC50 | 54.0000 | 1 | 1 |
| Transforming growth factor beta-1 proprotein | Mus musculus (house mouse) | IC50 | 1.4300 | 1 | 1 |
| Transient receptor potential cation channel subfamily M member 2 | Homo sapiens (human) | IC50 | 88.0000 | 2 | 3 |
| Transporter | Macaca mulatta (Rhesus monkey) | IC50 | 100.0000 | 1 | 1 |
| Transthyretin | Homo sapiens (human) | IC50 | 6.2600 | 5 | 5 |
| Trypsin-1 | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| Trypsin-2 | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| Trypsin-3 | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| Tumor necrosis factor | Homo sapiens (human) | IC50 | 10,310.0000 | 2 | 2 |
| Tumor necrosis factor ligand superfamily member 11 | Mus musculus (house mouse) | IC50 | 20.0000 | 1 | 1 |
| Tyrosinase | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| Ubiquitin carboxyl-terminal hydrolase isozyme L5 | Homo sapiens (human) | IC50 | 2,946.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 1-6 | Homo sapiens (human) | IC50 | 131.0000 | 1 | 3 |
| UDP-glucuronosyltransferase 1-6 | Homo sapiens (human) | Ki | 23.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | IC50 | 131.0000 | 1 | 3 |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | Ki | 52.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 1A10 | Homo sapiens (human) | Ki | 28.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 1A4 | Homo sapiens (human) | IC50 | 131.0000 | 1 | 3 |
| UDP-glucuronosyltransferase 1A7 | Homo sapiens (human) | Ki | 19.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 1A9 | Homo sapiens (human) | Ki | 11.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 2B10 | Homo sapiens (human) | IC50 | 131.0000 | 1 | 3 |
| UDP-glucuronosyltransferase 2B7 | Homo sapiens (human) | IC50 | 131.0000 | 1 | 3 |
| Uracil nucleotide/cysteinyl leukotriene receptor | Homo sapiens (human) | IC50 | 28.8000 | 2 | 2 |
| Urotensin-2 receptor | Rattus norvegicus (Norway rat) | IC50 | 3.9500 | 1 | 4 |